Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934292 | 0.89 | LTA4H (0.45) | LTA4HL3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL7385100 | 0.85 | SMN1; SMN2 (0.53) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL6623432 | 0.79 | EPHX2 (0.52) | PTGS2EPHX2 | |
| SCHEMBL29705753 | 0.77 | ALDH1A1 (0.51) | PTGS2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL17290963 | 0.76 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL6490290 | 0.75 | KMT2A (0.45) | LTA4HL3MBTL1KMT2AMEN1TAAR1 | |
| SCHEMBL2405923 | 0.74 | FOLH1 (0.42) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL13228080 | 0.73 | LMNA (0.47) | KMT2AMEN1ALDH1A1KDM4EEPHX2 | |
| SCHEMBL4462758 | 0.73 | HDAC3 (0.57) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL2662926 | 0.73 | LTA4H (0.55) | LTA4HL3MBTL1PTGS2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1392299-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-22 | — | — | US | disclosed |
| WO-2002094266-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | LTA4H 1727/4885L3MBTL1 3347/4885PTGS2 238/4885 |
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | LTA4H 1727/4885L3MBTL1 3347/4885PTGS2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.